Last reviewed · How we verify
Cisplatin Combined With Topotecan
Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while topotecan inhibits topoisomerase I, preventing DNA repair and replication.
Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while topotecan inhibits topoisomerase I, preventing DNA repair and replication. Used for Small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Cisplatin Combined With Topotecan |
|---|---|
| Sponsor | Chinese Anti-Cancer Association |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and transcription. Topotecan, on the other hand, is a topoisomerase I inhibitor that prevents the enzyme from unwinding DNA, thereby blocking DNA repair and replication. This dual mechanism of action makes cisplatin combined with topotecan a potent chemotherapeutic agent.
Approved indications
- Small cell lung cancer
- Ovarian cancer
Common side effects
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Diarrhea
- Fatigue
- Hearing loss
- Tinnitus
- Kidney damage
Key clinical trials
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (PHASE2)
- Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma (PHASE2)
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer (PHASE1)
- Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer (PHASE2)
- A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) (PHASE1, PHASE2)
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin Combined With Topotecan CI brief — competitive landscape report
- Cisplatin Combined With Topotecan updates RSS · CI watch RSS
- Chinese Anti-Cancer Association portfolio CI